Featured Content

Winston Wong, PharmD
President, W-Squared Group

U.S. Cancer Doctors Drop Pricey Drugs with Little or No Effect

(Reuters) Oct 8, 2015 - U.S. oncologists, aware that patients are paying more of the costs of expensive cancer drugs, are increasingly declining to prescribe medicines that have scant or no effect, even as a last resort.

Commentary: We should expect to see more report such as this. The ASCO frame work, in many respects, helps facilitate the...

OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Is This Cancer Treatment Worth It? New Tool Offers Patients Data

(Bloomberg) Oct 13, 2015 - For the first time, a consortium of top U.S. cancer hospitals will provide patients with guidance about the cost of drugs used in their treatment, helping address a concern for many people undergoing a major medical event -- what the financial repercussions of their condition are.
read article »

What Race Has to Do With Breast Cancer

(TIME) Oct 12, 2015 - Researchers provide the most detailed look yet at why minority women tend to fare worse with breast cancer.
read article »

Dueling Recommendations About Need For Pelvic Exams Leaves Women Confused

(Kaiser Health News) Oct 13, 2015 - It’s the latest battle over screening: Should healthy women skip annual pelvic exams?
read article »


View ALL News »

News Story Commentary By Academic and Community Oncologists

U.S. Cancer Doctors Drop Pricey Drugs with Little or No Effect (Reuters)

We should expect to see more report such as this. The ASCO frame work, in many respects, helps facilitate the...posted by: Winston Wong, PharmD

NCCN to Unveil Oncology Value Tool at Oct 16 Press Conference in San Francisco (NCCN)

This is a very needed advance to the NCCN guidelines, allowing oncologists to bring the value proposal to the patient....posted by: Winston Wong, PharmD

Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Expanded FDA Approval in Previously-Treated Metastatic Non-Small Cell Lung Cancer (NSCLC), Offering Improved Survival to More Patients (Bristol-Myers)

Not unexpected, but long awaited after a clinically significant survival benefit was reported at ASCO. I think...posted by: H. Jack West, MD

FDA Approves Keytruda For Advanced Non-Small Cell Lung Cancer (FDA.gov)

This is clearly an important approval, but with nivolumab already approved for squamous NSCLC and listed as a recommended...posted by: H. Jack West, MD

FDA Approves Pembrolizumab for Lung Cancer (Medscape Medical News)

This approval presents an epic problem: to obtain a companion diagnostic (pembro) or not to obtain a companion...posted by: Dean Gesme, MD

OBR Training

Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.

OBR Job Board

Ipsen has 1 new job posted.

Dava Oncology has 1 new job posted.

Bayer has 7 jobs posted.

Seattle Genetics has 3 jobs posted.

Check out the OBR Job Board here.

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™

View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.


Symbol  %Δ
MGNX +5.49%
ADAP +4.87%
CVM +4.41%
SNSS -12.49%
NYMX -11.61%
CRIS -9.95%


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results

Date: October 23, 2015
Company: Spectrum Pharmaceuticals
Product: Evomela™ (melphalan hydrochloride) for injection

Date: October 24, 2015
Company: Merrimack Pharmaceuticals / Baxalta Inc.
Product: MM-398 (irinotecan liposome injection), also known as "nal-IRI"

Date: October 27, 2015
Company: Amgen / Onyx
Product: talimogene laherparepvec (T-Vec)

See All OBR Radar items»

OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.